ORDER ARTESUNATE – USA
A time-critical drug for treating severe malaria

Note: Please use the emergency ordering numbers below (do not use your regular ordering phone numbers)
*In the event you are unable to procure product urgently, please obtain product from any other distributor
AMERISOURCEBERGEN ASD HEALTHCARE
1-800-746-6273
CARDINAL HEALTH SPECIALITY PHARMACEUTICAL DISTRIBUTION
1-866-677-4844
MCKESSON PLASMA & BIOLOGICS
1-877-625-2566
AMERISOURCEBERGEN FULL LINE HEALTHCARE
1-844-222-2273 (NOT 24/7)
FFF ENTERPRISES
1-800-843-7477
FOR NON-EMERGENCY ORDERING:
CARDINAL HEALTH – 3PL Services – via email GMB-SPS-Amivas@cordlogistics.com
FFF ENTERPRISES -Distribution and Consignment – via email AcuteCareClientManagers@fffenterprises.com
AMIVAS MEDICAL AFFAIRS – OPEN 24/7/365 1-855-5AMIVAS
*Healthcare professionals with product related questions including difficulties obtaining product emergently from our distributors should contact the Amivas Medical Affairs immediately
Note: Please leave a voice message with your contact number for a PATIENT EMERGENCY. All voice messages will be called back within 30 minutes.
EMERGENCY MEDICAL ADVICE:
Healthcare professionals who would like a consultation regarding how to treat a patient who has severe malaria can contact the CDC at (770) 488-7788 Mon – Fri, 9am–5pm EST. After hours, call (770) 488-7100
**The CDC has discontinued distribution of unregistered Intravenous Artesunate.
CDC has provided advice on the timely treatment of malaria at the following link:
Download a PDF of the ordering instructions
Download Artesunate – USA Ordering Instructions.
Download a PDF of the ordering instructions
Return Goods Policy
Download our January 1st, 2025 Return Goods Policy (PDF).
If the product was purchased through FFF Enterprises, please contact them directly.
Registering Artesunate use during pregnancy
Please register treatments of pregnant women by enrolling in our study.
- Call 1-855-526-4827 (1-855-5AMIVAS)
- Press option 2 on IVR.
The treatment will be registered with AMIVAS’ Observational Study of the Safety of Intravenous Artesunate Treatment of Pregnant Women and their Infants Registry.